Survival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system

Neurosurgery

Volumn 42, Issue 2, 1998, Pages 335-340

  Griffitt, Wesley ^a,c   Glick, Roberta P ^a,b,c   Lichtor, Terry ^a,c   Cohen, Edward P ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Jr Hospital of Cook County   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Allogeneic fibroblasts; Brain tumors; Cytokines; Immune rejection; Interleukin 2; Polymerase chain reaction

Indexed keywords

INTERLEUKIN 2;

ALLOGENEIC RESTRICTION; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; FEMALE; FIBROBLAST; GLIOBLASTOMA; INTRACEREBRAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0031908884     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199802000-00075     Document Type: Article

References (24)

1. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175-182, 1989.
2. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987.
3. Fearon ER, Itaya T, Hunt B, Vogelstein B, Frost P: Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res 48:2975-2980, 1988.
4. d into a human colon cancer cell line (HCT). Proc Natl Acad Sci U S A 85:8543-8547, 1988.
5. Gillis S, Ferm MM, Ou W, Smith KA: T cell growth factors: Parameters of production and a quantitative microassay for activity. J Immunol 120:2027-2032, 1978.
6. Glick RP, Lichtor T, Kim TS, Taylor C, Griffitt W, Cohen EP: Immuno-gene therapy for intracerebral melanoma. Cancer Gene Therapy 2:311-312, 1995.
7. Hammerling GJ, Klar D, Katzav S, Segal S, Feldman M, Wallich R, Hammerling A: Manipulation of metastasis and tumor growth by transfection with histocompatibility Class I genes. J Immunogen 13:15-17, 1986.
8. Hui KM, Sim TF, Foo TT, Oie A-A: Tumor rejection mediated by transfection with allogeneic Class I histocompatibility gene. J Immunol 143:3835-3843, 1989.
9. Kim TS, Russell SJ, Collins MKL, Cohen EP: Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer 51:283-289, 1992.
10. Kim YS, Slomski R, Cohen EP: Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens. Cancer Immunol Immunother 34:163-168, 1991.
11. Lichtor T, Glick RP, Kim TS, Hand R, Cohen EP: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83:1038-1044, 1995.
12. Mahaley MS Jr, Mettlin C, Natarajan N, Laws ER Jr, Peace BA: National survey of patterns of care for brain-tumor patients. J Neurosurg 71:826-836, 1989.
13. Merchant RE, Ellison MD, Young HF: Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes: A review of preclinical and clinical investigation. J Neurooncol 8:173-188, 1990.
14. Merchant RE, McVicar DW, Merchant LH, Young HF: Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α: Results of a Phase I clinical trial. J Neurooncol 12:75-83, 1992.
15. Ostrand-Rosenberg S, Thakur A, Clements V: Rejection of mouse sarcoma cells after transfection of MHC Class II genes. J Immunol 144:4068-4071, 1990.
16. Ram Z, Walbridge S, Heiss JD, Culver KW, Blaese RM, Oldfield EH: In vivo transfer of the human interleukin-2 gene: Negative tumoricidal results in experimental brain tumors. J Neurosurg 80:535-540, 1994.
17. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987.
18. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271: 907-913, 1994.
19. Saris SC, Spiess P, Lieberman DM, Lin S, Walbridge S, Oldfield EH: Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76:513-519, 1992.
20. Streilein WJ: Unraveling immune privilege. Science 270:1158-1159, 1995.
21. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matie C, Koutcher J, Gilboa E, Blasberg G: RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Cancer Res 55:1902-1910, 1995.
22. Wigler M, Pellicer A, Silverstein S, Axel R: Biochemical transfer of single-copy eukaryotic genes using total cellular DNA as donor. Cell 14:725-731, 1978.
23. Yamada G, Kitamura Y, Sonoda H, Harada H, Taki S, Mulligan RC, Ossawa H, Diamanstein T, Yokoyama S, Taniguchi T: Retroviral expression of human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J 6:2705-2709, 1987.
24. Yu JS, Wei MX, Chiocca A, Martuza RL, Tepper RI: Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 53:3125-3128, 1993.